Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of hemorrhagic risk in Alzheimer's disease. 2 key findings →
Design: longitudinal study
Participants: 1,069
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
These results indicate a strong association between WMH and MCH, a common manifestation of cerebral amyloid angiopathy and ARIA-H. These results suggest that increased WMH volume may represent an early sign of vessel amyloidosis, likely prior to the emergence of MCH. 4 key findings →
Design: longitudinal study
Evidence: high
Full summary, score breakdown and related studies →
Original source
Four regulatory agencies have approved lecanemab through different pathways, each requiring confirmation of amyloid pathology and careful assessment of ARIA risk, particularly in Apolipoprotein E (ApoE) ε4 homozygotes. 5 key findings →
Design: cohort study
Participants: 407
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
MCH-Guard offers a flexible clinical decision-support tool for optimizing spontaneous MCH and ARIA-H surveillance. 1 key finding →
Design: longitudinal study
Participants: 813
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
78/100
✓ Peer-reviewed
alzhub usefulness score 78 out of 100.
·
JAMA neurology
·
2025-01-01
Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target. 5 key findings →
Design: longitudinal study
Participants: 167
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Lower baseline C3 was consistently associated with ARIA risk across sensitivity analyses and higher baseline C1q with smaller amyloid reduction at week 26. 4 key findings →
Design: cohort study
Participants: 62
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
In this prospective Korean cohort, lecanemab was generally well tolerated. 3 key findings →
Design: longitudinal study
Participants: 127
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Compared with an AChEI-based conventional care strategy, lecanemab initiation was associated with comparable treatment persistence and lower observed risks of BPSD, emergency visit as well as reduced use of psychotropic and infection-related medications in exploratory analyses. 5 key findings →
Design: cohort study
Participants: 589
Evidence: high
Full summary, score breakdown and related studies →
Original source
76/100
✓ Peer-reviewed
alzhub usefulness score 76 out of 100.
·
BMJ
·
2024-04-17
Antipsychotic use compared with non-use in adults with dementia was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, and acute kidney injury, but not ventricular arrhythmia. 5 key findings →
Design: cohort
Participants: 173,910
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Our single-center experience with long-term lecanemab treatment was similar to that observed in clinical trials. 3 key findings →
Design: cohort study
Participants: 136
Evidence: high
Full summary, score breakdown and related studies →
Original source
75/100
✓ Peer-reviewed
alzhub usefulness score 75 out of 100.
·
JAMA network open
·
2024-10-01
There were 132 846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159 419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92 328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]). 5 key findings →
Design: cohort study
Participants: 846
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
74/100
✓ Peer-reviewed
alzhub usefulness score 74 out of 100.
·
JAMA neurology
·
2020-12-01
Compared with participants who learned that they had a not elevated amyloid result, individuals who learned of an elevated amyloid result were no more likely to experience short-term increases in depression (mean [SD] change in the Geriatric Depression Scale score, 0.02 [1.3] vs 0.04 [1.3]; P = .90), anxiety (mean [SD] change in State-Trait Anxiety Inventory score, -0.02 [3.2] vs -0.15 [3.0]; P = .65), or suicidality (mean [SD] change in the Columbia Suicide Severity Rating Scale score, 0.0 [0.4] vs -0.01 [0.5]; P = .67). 5 key findings →
Design: cohort study
Participants: 1,167
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
These findings support the short-term efficacy and safety of Lecanemab in early AD and highlight plasma biomarkers as a treatment-responsive biomarker. 3 key findings →
Design: cohort study
Participants: 68
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Based on family informant reports and clinical observations, the median age at onset (AAO) among affected individuals in these pedigrees was 48.50 (44.0, 51.8) years. 5 key findings →
Design: longitudinal study
Participants: 206
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
JAMA neurology
·
2021-11-01
Of 200 participants, 99 were assigned to methylphenidate and 101 to placebo. 5 key findings →
Design: longitudinal study
Participants: 200
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
The study included 524,975 older adults with dementia who were incident users of ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%). 5 key findings →
Design: cohort study
Participants: 524,975
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
Drugs & aging
·
2021-05-24
The study included 47,059 older adults with dementia who were incident users of AChEIs. 5 key findings →
Design: cohort study
Participants: 47,059
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
73/100
✓ Peer-reviewed
alzhub usefulness score 73 out of 100.
·
Drugs & aging
·
2021-03-25
The study cohort consisted of 178,441 older adults with dementia who were new users of ChEIs. 5 key findings →
Design: cohort study
Participants: 23,433
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Lecanemab was generally well tolerated by most patients with early AD and treatment appeared to be more effective and safer in patients with low CSF-ptau181 levels. 5 key findings →
Design: longitudinal study
Participants: 234
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
7T MRI provides superior ARIA-H detection and iron dynamics monitoring, supporting its role in risk stratification and therapy assessment for lecanemab-treated patients. 3 key findings →
Design: longitudinal study
Participants: 72
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
71/100
✓ Peer-reviewed
alzhub usefulness score 71 out of 100.
·
JAMA Neurology
·
2025-07-01
The most significant adverse events associated with these therapies are infusion-related reactions and amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and/or hemorrhage/hemosiderin deposition (ARIA-H). 5 key findings →
Design: cohort
Participants: 234
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Between July 2023 and January 2025, 169 patients were screened and 86 initiated lecanemab treatment. 5 key findings →
Design: longitudinal study
Participants: 31
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
In our final study sample (N = 21,558), significant difference in survival among index AD medication groups were observed with donepezil being associated with better survival than memantine, and oral and transdermal forms of rivastigmine for both ITT and as-treated analysis. 3 key findings →
Design: cohort study
Participants: 21,558
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Further investigations are needed to determine the optimal measures with which to quantify and qualify QOL of patients with mild AD. 1 key finding →
Design: longitudinal study
Participants: 1,322
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
The mean age was 66 years (65.53 ± 9.31), and 51 (67.1%) participants being female. 5 key findings →
Design: cohort study
Participants: 14
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 33,780 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.